Our top pick for
Building a portfolio
Onconova Therapeutics, Inc is a biotechnology business based in the US. Onconova Therapeutics shares (ONTX) are listed on the NASDAQ and all prices are listed in US Dollars. Onconova Therapeutics employs 11 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.19 - $1.87|
|50-day moving average||$1.04|
|200-day moving average||$0.65|
|Wall St. target price||$2.10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.81|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Onconova Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Onconova Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Onconova Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Onconova Therapeutics shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||$231,000|
|Return on assets TTM||-71.56%|
|Return on equity TTM||-283.48%|
|Market capitalisation||$149.1 million|
TTM: trailing 12 months
There are currently 10.2 million Onconova Therapeutics shares held short by investors – that's known as Onconova Therapeutics's "short interest". This figure is 12.4% down from 11.6 million last month.
There are a few different ways that this level of interest in shorting Onconova Therapeutics shares can be evaluated.
Onconova Therapeutics's "short interest ratio" (SIR) is the quantity of Onconova Therapeutics shares currently shorted divided by the average quantity of Onconova Therapeutics shares traded daily (recently around 23.7 million). Onconova Therapeutics's SIR currently stands at 0.43. In other words for every 100,000 Onconova Therapeutics shares traded daily on the market, roughly 430 shares are currently held short.
However Onconova Therapeutics's short interest can also be evaluated against the total number of Onconova Therapeutics shares, or, against the total number of tradable Onconova Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Onconova Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Onconova Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0432% of the tradable shares (for every 100,000 tradable Onconova Therapeutics shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Onconova Therapeutics.
Find out more about how you can short Onconova Therapeutics stock.
We're not expecting Onconova Therapeutics to pay a dividend over the next 12 months.
Onconova Therapeutics's shares were split on a 1:15 basis on 25 September 2018. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Onconova Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Onconova Therapeutics shares which in turn could have impacted Onconova Therapeutics's share price.
Over the last 12 months, Onconova Therapeutics's shares have ranged in value from as little as $0.19 up to $1.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Onconova Therapeutics's is 1.7612. This would suggest that Onconova Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.